中华皮肤科杂志 ›› 2025, Vol. 58 ›› Issue (9): 856-859.doi: 10.35541/cjd.20240500

• 临床经验 • 上一篇    下一篇

巴瑞替尼联合芦可替尼乳膏治疗6例进展期非节段型白癜风患者的疗效观察

朱婷婷1，2    李蔚然2    潘召兵3    刘昊4    唐先发2    朱才红2    黄鹤群2    段大威2    张若晨5    陈小建5    汪洋2    薛倩2    张菊锐1    杨丽婧1    张学军1，2    黄贺1，2    张博1，2   

  1. 1海南博鳌超级医院皮肤医学中心，琼海  571437；2安徽医科大学第一附属医院皮肤性病科  安徽医科大学皮肤病研究所，合肥  230022；3海南省皮肤病医院，海口  570100；4海南医科大学第二附属医院皮肤科，海口  570311；5苏州大学附属第四医院皮肤科，苏州  215000
  • 收稿日期:2024-09-19 修回日期:2025-06-18 发布日期:2025-09-01
  • 通讯作者: 张博 E-mail:alvinbo@163.com
  • 基金资助:
    皮肤病学教育部重点实验室开放基金项目（AYFYS2024-5）

Efficacy of baricitinib combined with ruxolitinib cream in the treatment of six patients with progressive nonsegmental vitiligo: a clinical observation

Zhu Tingting1,2, Li Weiran2, Pan Zhaobing3, Liu Hao4, Tang Xianfa2, Zhu Caihong2, Huang Hequn2, Duan Dawei2, Zhang Ruochen5, Chen Xiaojian5, Wang Yang2, Xue Qian2, Zhang Jurui1,Yang Lijing1,Zhang Xuejun1,2, Huang He1,2, Zhang Bo1,2   

  1. 1Dermatology Center, Boao Super Hospital, Qionghai 571437, Hainan, China; 2Department of Dermatology and Venereology, the First Affiliated Hospital, Institute of Dermatology, Anhui Medical University, Hefei 230022, China; 3Hainan Provincial Dermatology Hospital, Haikou 570100, China; 4Department of Dermatology, the Second Affiliated Hospital of Hainan Medical University, Haikou 570311, China; 5Department of Dermatology, the Fourth Affiliated Hospital of Soochow University, Suzhou 215000, Jiangsu, China
  • Received:2024-09-19 Revised:2025-06-18 Published:2025-09-01
  • Contact: Zhang Bo E-mail:alvinbo@163.com
  • Supported by:
    Open Fund Project of Key Laboratory of Dermatology, Ministry of Education（AYFYS2024-5）

PDF

1

摘要： 【摘要】 目的 观察巴瑞替尼联合芦可替尼乳膏治疗进展期非节段型白癜风患者的疗效及不良反应。方法 回顾性收集在海南博鳌超级医院就诊的进展期非节段型白癜风患者，均采用巴瑞替尼（体重 ≤ 50 kg，2 mg/d；体重 > 50 kg，4 mg/d）口服联合芦可替尼乳膏外用每天2次，治疗24周。采用面部和全身白癜风面积评分指数（VASI）对基线、12周、24周的疾病表现进行评估，同时监测治疗过程中的不良反应。结果 6例进展期非节段型白癜风患者，男女各3例，年龄26 ~ 42岁，病程0.5 ~ 25年。治疗12周，与基线相比，3例面部白癜风改善 ≥ 50% ~ < 75%（面部VASI 50），1例达到面部VASI 75（≥ 75% ~ < 90%），1例达到全身VASI 50；治疗24周，4例达到面部VASI 50，1例达到面部VASI 75，1例达到面部VASI 90（≥ 90%），3例达到全身VASI 50。治疗过程中，1例出现上呼吸道感染，1例出现痤疮，2例出现瘙痒，2例出现总胆固醇升高，2例出现高密度脂蛋白升高，未观察到严重不良事件。结论 巴瑞替尼联合芦可替尼乳膏治疗进展期非节段型白癜风可能具有潜在疗效及安全性。

关键词: 白癜风, Janus激酶抑制剂, 巴瑞替尼, 芦可替尼, 治疗结果, 有效性, 安全性

Abstract: 【Abstract】 Objective To evaluate the efficacy and safety of baricitinib combined with ruxolitinib cream in the treatment of progressive nonsegmental vitiligo. Methods Clinical data were retrospectively collected from patients with progressive nonsegmental vitiligo in Boao Super Hospital. All the patients were treated with oral baricitinib daily （2 mg/day for patients weighing ≤ 50 kg; 4 mg/day for those > 50 kg） in combination with topical application of ruxolitinib cream twice daily for 24 consecutive weeks. Disease severity was assessed using the facial vitiligo area scoring index （F-VASI） and total body VASI （T-VASI） at baseline, week 12, and week 24. Adverse reactions were monitored throughout the treatment course. Results Six patients with progressive nonsegmental vitiligo were collected, including 3 males and 3 females, aged 26 - 42 years, with the disease duration ranging from 0.5 to 25 years. At week 12, 3 patients achieved a 50% ~ < 75% improvement in facial vitiligo lesions （F-VASI 50）, 1 patient achieved F-VASI 75 （75% ~ < 90% improvement）, and 1 patient achieved T-VASI 50; at week 24, 4 patients achieved F-VASI 50, 1 patient achieved F-VASI 75, 1 patient achieved F-VASI 90 （≥ 90% improvement）, and 3 patients achieved T-VASI 50. During the treatment, upper respiratory infection occurred in 1 patient, acne in 1 patient, pruritus in 2 patients, elevation of total cholesterol levels in 2 patients, and increase of high-density lipoprotein levels in 2 patients. No severe adverse events were observed during the treatment. Conclusion The combination therapy with baricitinib and ruxolitinib cream may have potential efficacy and safety in the treatment of progressive nonsegmental vitiligo.

Key words: Vitiligo, Janus kinase inhibitors, Baricitinib, Ruxolitinib, Treatment outcome, Efficacy, Safety

引用本文

朱婷婷, 李蔚然 潘召兵 刘昊 唐先发 朱才红 黄鹤群 段大威 张若晨 陈小建 汪洋 薛倩 张菊锐 杨丽婧 张学军, 黄贺, 张博, . 巴瑞替尼联合芦可替尼乳膏治疗6例进展期非节段型白癜风患者的疗效观察[J]. 中华皮肤科杂志, 2025,58(9):856-859. doi:10.35541/cjd.20240500

Zhu Tingting, Li Weiran, Pan Zhaobing, Liu Hao, Tang Xianfa, Zhu Caihong, Huang Hequn, Duan Dawei, Zhang Ruochen, Chen Xiaojian, Wang Yang, Xue Qian, Zhang Jurui, Yang Lijing, Zhang Xuejun, Huang He, Zhang Bo, . Efficacy of baricitinib combined with ruxolitinib cream in the treatment of six patients with progressive nonsegmental vitiligo: a clinical observation[J]. Chinese Journal of Dermatology, 2025, 58(9): 856-859.doi:10.35541/cjd.20240500